DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Regorafenib
Regorafenib
Oncology – Tasigna® (Nilotinib Capsules)
Nilotinib (Tasigna®) EOCCO POLICY
Fasting Potentiates the Anticancer Activity of Tyrosine Kinase Inhibitors by Strengthening MAPK Signaling Inhibition
Tasigna
BC Cancer Benefit Drug List September 2021
Systematic Review: Targeting HER2 in Bladder Cancer
CP.PHAR.76 Nilotinib (Tasigna)
Tasigna (Nilotinib)
Phase I/II Trial of Ruxolitinib in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer
Cabozantinib and the Moving Field of Systemic Treatments in Advanced Hepatocellular Carcinoma
Regorafenib(Stivarga°)
A Systematic Review and Network Meta-Analysis of Second-Line Therapy in Hepatocellular Carcinoma
TASIGNA (Nilotinib) RATIONALE for INCLUSION in PA PROGRAM
Promising Therapeutics of Gastrointestinal Cancers in Clinical Trials
Assessment Report
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Regorafenib-Attenuated, Bleomycin-Induced Pulmonary Fibrosis by Inhibiting the TGF-Β1 Signaling Pathway
Regorafenib – Five Years in Review
Top View
Multicenter Retrospective Analysis of the Safety and Efficacy of Regorafenib After Progression on Sorafenib in Korean Patients with Hepatocellular Carcinoma
Survival in Advanced GIST Has Improved Over Time and Correlates
For Health Professionals Who Care for Cancer Patients
Tasigna® (Nilotinib)
DAIICHI SANKYO CO., LTD. Sunao Manabe President and CEO June 8, 2021
Regorafenib > Printer-Friendly PDF
Clinical Pharmacology Biopharmaceutics Review(S)
Gastrointestinal Stromal Tumors: What Do We Know Now? Christopher L Corless
Caresource Prior Authorization Criteria (Updated November, 2018)
Regorafenib (Stivarga) National Drug Monograph February/March 2013 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll
Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the Ifng/STAT1 Signaling in Hepatocellular Carcinoma Cells
Histone Deacetylase Inhibitor Resminostat in Combination with Sorafenib Counteracts Platelet-Mediated Pro-Tumoral Effects In
Reimbursement Criteria for Frequently Requested Drugs
Regorafenib (Stivarga) Is an Orally Administered Kinase Inhibitor Acting on Various Membrane-Bound and Intracellular Kinases
Stivarga, INN-Regorafenib
Ipsen – MAIC – 19 May 2020
Targeting HER2 with Trastuzumab Deruxtecan: a Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors